双嘧达莫联合甲泼尼龙治疗过敏性紫癜患儿的效果

Effects of Dipyridamole combined with Methylprednisolone in treatment of children with Henoch-Schonlein purpura

目的:观察双嘧达莫联合甲泼尼龙治疗过敏性紫癜(HSP)患儿的效果。方法:回顾性分析2021年10月至2023年10月该院收治的80例HSP患儿的临床资料,根据治疗方法不同将其分为对照组和观察组各40例。两组均给予常规治疗,在此基础上对照组给予甲泼尼龙治疗,观察组在对照组基础上联合双嘧达莫治疗。比较两组临床症状消失时间,治疗前后炎性因子[可溶性肿瘤生成抑制素2(sST_(2))、转化生长因子-β(TGF-β)、白细胞介素-6(IL-6)、C反应蛋白(CRP)]、免疫球蛋白指标[免疫球蛋白(Ig)A、IgA1、IgE、IgM、凝血功能指标[活化部分凝血活酶时间(APTT)、凝血酶原时间(PT)、D-二聚体(D-D)]水平,以及不良反应发生率。结果:观察组皮疹、关节肿痛、蛋白尿、腹痛消失时间均短于对照组,差异有统计学意义(P<0.05);治疗后,两组sST_(2)、TGF-β、CRP、IL-6水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组IgA、IgA1、IgM、IgE水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);治疗后,两组APTT、PT均长于治疗前,且观察组长于对照组,两组D-D水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:双嘧达莫联合甲泼尼龙治疗HSP患儿可缩短临床症状消失时间,改善凝血功能指标水平,以及降低炎性因子指标水平和免疫球蛋白指标的效果优于单纯甲泼尼龙治疗。

Objective:To observe effects of Dipyridamole combined with Methylprednisolone in treatment of children with Henoch-Schonlein purpura(HSP).Methods:The clinical data of 80 children with HSP admitted to this hospital from October 2021 to October 2023 were retrospectively analyzed.According to different treatment methods,they were divided into control group and observation group,40 cases in each group.Both groups were given routine treatment.On this basis,the control group was treated with Methylprednisolone,while the observation group was treated with Dipyridamole on the basis of that of the control group.The disappearance time of clinical symptoms,the levels of inflammatory factors[soluble tumor suppressor 2(sST_(2)),transforming growth factor-β(TGF-β),interleukin-6(IL-6),C-reactive protein(CRP)],immunoglobulin[immunoglobulin(Ig)A,IgA1,IgE,IgM and coagulation function indexes[activated partial coagulation time(APTT),prothrombin time(PT),D-dimer(D-D)]before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The disappearance time of rash,joint swelling and pain,proteinuria and abdominal pain in the observation group were shorter than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of sST_(2),TGF-β,CRP and IL-6 in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).The levels of IgA,IgA1,IgM and IgE in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the APTT and PT in the two groups were longer than those before the treatment,and those in the observation group were longer than those in the control group;the D-D levels of the two groups were lower than those before the treatment,and that in the observation group was lower than that in the control group;and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Dipyridamole combined with Methylprednisolone in the treatment of the children with HSP can shorten the disappearance time of clinical symptoms,improve the levels of coagulation function indexes,and reduce the levels of inflammatory factors and immunoglobulin indexes.Moreover,it is superior to simple Methylprednisolone treatment.